Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients

Metabolism: Clinical and Experimental

Volumn 60, Issue 3, 2011, Pages 421-429

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   D'Angelo, Angela ^a   Palumbo, Ilaria ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ADIPONECTIN; C REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN GLULISINE; INSULIN LISPRO; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SIBUTRAMINE; SITAGLIPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASPIN; VILDAGLIPTIN;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE INDEX; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; APPETITE DEPRESSANTS; BLOOD GLUCOSE; BODY WEIGHT; C-REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; LEPTIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN B COMPLEX;

EID: 79951788858     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2010.03.010     Document Type: Article

References (50)

1. Fried M, Hainer V, Basdevant A, et al. Interdisciplinary European guidelines on surgery for severe obesity. Rozhl Chir 2008;87:468-76.
2. Pagotto U, Vanuzzo D, Vicennati V, Pasquali RG. Pharmacological therapy of obesity. G Ital Cardiol (Rome) 2008;9(4 Suppl 1):83S-93S.
3. Marović D. Elevated body mass index fatty liver. Srp Arh Celok Lek 2008;136:122-5.
4. Lavie CJ, Artham SM, Milani RV, Ventura HO. The obesity paradox: impact of obesity on the prevalence prognosis of cardiovascular diseases. Postgrad Med 2008;120:34-41.
5. American Diabetes Association. Nutrition principles and recommendations in diabetes. Diabetes Care 2004;27(S1):36-46.
6. American Diabetes Association. Physical activity/exercise and diabetes. Diabetes Care 2004;27(S1):58-62.
7. Lee M, Aronne LJ. Weight management for type 2 diabetes mellitus: global cardiovascular risk reduction. Am J Cardiol 2007;99:68B-79B.
8. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-7. (Pubitemid 46027230)
9. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs 1998;56:1093-124. (Pubitemid 29010230)
10. Abbott Laboratories limited. Sibutramine, summary of product characteristic. Abbot Park (Ill): Abbott laboratories; 2000.
11. Uziel G, Garavaglia B, Di Donato S. Carnitine stimulation of pyruvate dehydrogenase complex (PDHC) in isolated human skeletal muscle mitochondria. Muscle Nerve 1988;11:720-4.
12. Derosa G, Cicero AFG, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003;25:1429-39. (Pubitemid 36677286)
13. Amat di San Filippo C, Taylor MR, Mestroni L, Botto LD, Longo N. Cardiomyopathy carnitine deficiency. Mol Genet Metab 2008;94:162-6.
14. Newsholme EA, Leech AR. Biochemistry for medical sciences. Chichester: John Wiley and Sons; 1983. p. 318-21.
15. Rydén L, Standl E, Bartnik M, et al. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
16. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO consultation on obesity. Geneva: WHO; 1997.
17. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006;26:2186-91.
18. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978;200:21-7.
19. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 1999;16:716-30.
20. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972;8:260-6.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9. (Pubitemid 15018832)
22. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-95. (Pubitemid 38680001)
23. Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem 1978;15:121-30. (Pubitemid 8061822)
24. Wahlefeld AW. Methods of enzymatic analysis: triglycerides determination after enzymatic hydrolysis. Nergmer HV ed. New York: Academic Press, Inc.; 1974. p. 18-31.
25. Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955;34:1345-53.
26. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
27. Misra A, Garg A. Leptin: its receptor and obesity. J Invest Med 1996;44:540-8.
28. Zhang M, Tracey K. The cytokine handbook. 3rd ed. San Diego: Academic Press; 1988.
29. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 2001;7:941-6. (Pubitemid 32756432)
30. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci 2005;102:10610-5. (Pubitemid 41061602)
31. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136-41.
32. Winer BJ. Statistical principles in experimental design. 2nd ed. New York: McGraw-Hill; 1971.
33. Sirtori CR, Calabresi L, Ferrara S, et al. L-Carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovas Dis 2000;10:247-51.
34. Derosa G, D'Angelo A, Salvadeo SAT, et al. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. Metabolism 2008;57:1552-7.
35. Derosa G, Mereu R, Salvadeo SAT, et al. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. Inter Med 2009;48:265-71.
36. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004;116:337-50. (Pubitemid 38167322)
37. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-4. (Pubitemid 27446179)
38. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91. (Pubitemid 23036092)
39. Hotamisligil GS. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-5. (Pubitemid 29278870)
40. Jackson MB, Ahima RS. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clinical Science 2006;110:143-52. (Pubitemid 43241476)
41. Berg AH, Combs TP, Scherer PE. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002;13:84-9.
42. Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity? Int J Obes Relat Metab Disord 2005;29(Suppl 1):S17-23.
43. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002;8:731-7. (Pubitemid 34778727)
44. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001;7:947-53.
45. Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008;57:372-7.
46. Klöting N, Berndt J, Kralisch S, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339:430-6. (Pubitemid 41697566)
47. Zvonic S, Lefevre M, Kilroy G, et al. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol Cell Proteomics 2007;6:18-28. (Pubitemid 46152688)
48. Zwacka TP, Hornbach V, Torzewski J. C-reactive protein-mediated lipoprotein uptake by macrophages. Circulation 2001;103:1194-7.
49. Derosa G, Cicero AFG, Murdolo G, et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab 2005;7:47-55.
50. Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. Diabetes Nutr Metab 2004;17:222-9. (Pubitemid 39496911)